Experimental pill promises new hope for deadly pancreatic cancer
The daily pill cut median survival to 13.2 months versus 6.7 months for chemotherapy in a randomized trial of 500 patients.
- On Sunday at the American Society for Clinical Oncology meeting in Chicago, researchers reported that the experimental pill daraxonrasib nearly doubled survival times for patients with advanced pancreatic cancer compared to chemotherapy.
- The drug targets the mutated KRAS gene, found in more than 90 per cent of pancreatic tumours, which continuously signals cancer cells to grow and was long considered 'undruggable' by researchers.
- In the 500-patient trial, daraxonrasib recipients lived a median of 13.2 months versus 6.7 months for chemotherapy patients, with severe side effects in 43.6 per cent of cases compared to 57.5 per cent on chemotherapy.
- Dr. Rachna Shroff of the Arizona Cancer Center called the results 'landscape-changing,' while the Food and Drug Administration plans to expedite review of the drug as a potential new standard of care.
- Researchers are now exploring whether daraxonrasib might shrink tumors to allow for surgery in earlier-stage patients, while the agency currently allows 'expanded access' to the experimental treatment for patients meeting specific criteria.
57 Articles
57 Articles
Revolution Medicines’ RVMD Phase 3 daraxonrasib data in metastatic pancreatic cancer cut death risk 60% and doubled survival—see implications now.
Experimental pill nearly doubles survival time for people with advanced pancreatic cancer. 'I actually started crying'
The drug is called daraxonrasib and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for decades.
New drug offers ‘large step forward’ to treat advanced pancreatic cancer
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer.
Experimental pill shows promise for deadly pancreatic cancer
Washington: A novel pill has helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes for improved treatments for one of the deadliest types of cancer.“While not curing the cancer, it is a very large step forward,” said Dr Zev Wainberg of the University of California, Los Angeles, who helped lead the study.The drug, called daraxonrasib, blocks a mutated protein that fuels tumour growth in more than 90…
Coverage Details
Bias Distribution
- 53% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
